VIVIMUSTA 25 mg/mL (Bendamustine Hydrochloride INJECTION) 25 mg/mL

Vivimusta 25 mg/mL is a bendamustine hydrochloride injection used for intravenous administration. This medication is designed to support certain cancer treatments, offering a convenient multi-dose vial option.

Strength

25 mg/mL

Pack Size

1 VIAL, MULTI-DOSE in 1 CARTON (24338-270-01) / 4 mL in 1 VIAL, MULTI-DOSE

Manufacturer / TM Owner

Azurity Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Vivimusta 25 mg/mL is primarily used in the treatment of various types of cancer. Bendamustine hydrochloride, the active ingredient, is often utilized in chemotherapy regimens to help manage certain hematological malignancies. Patients and healthcare providers commonly seek bendamustine for its role in cancer therapy, particularly in conditions where intravenous administration is preferred.

Side Effects

When administered as directed, Vivimusta 25 mg/mL may cause common side effects such as nausea, fatigue, and low blood cell counts. These effects can vary among individuals and are typically managed with supportive care. It is important to discuss any concerns about side effects with a healthcare provider.

Precautions & Warnings

Vivimusta 25 mg/mL should be handled with care, as it is a potent medication. It is essential to follow proper storage and administration guidelines to ensure safety. Patients should be monitored for any adverse reactions, and the medication should be used under the supervision of a qualified healthcare professional.

Avoid Interactions

Bendamustine hydrochloride can interact with other medications, including those that suppress the immune system or affect blood cell production. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain over-the-counter drugs may also interact with bendamustine, so caution is advised.

References

Frequently Asked Questions

Vivimusta 25 mg/mL is used in the treatment of certain types of cancer, typically as part of a chemotherapy regimen.

Vivimusta 25 mg/mL is administered intravenously by a healthcare professional, following proper medical guidelines.

Common side effects may include nausea, fatigue, and low blood cell counts. Always consult a healthcare provider for personalized advice.

Bendamustine hydrochloride can interact with other medications, so it is important to discuss all current medications with a healthcare provider.

Vivimusta 25 mg/mL should be stored according to the manufacturer's instructions to maintain its effectiveness and safety.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.